Deal watch: dipping into Incyte's JAK-pot.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors*; D009570:Nitriles; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines
D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; C507904:JAK1 protein, human; C507924:JAK2 protein, human; D053613:Janus Kinase 1; D053614:Janus Kinase 2